JordanK, HinkeA, GrotheyA, et al.: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 2007; 15:1023–1033.
2.
IoannidisJP, HeskethPJ, LauJ: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol, 2000; 18:3409–3422.
3.
GrunbergS, ChuaD, MaruA, et al.: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol—EASE. J Clin Oncol, 2011; 29:1495–1501.
4.
RoilaF, HerrstedtJ, AaproM, et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol, 2010; 21:232–243.
5.
BaschE, PrestrudAA, HeskethPJ, et al.: Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol, 2011; 29:4189–4198.
SternRM, KochKL, AndrewsPLR (eds): Nausea: Mechanisms and Management. New York: Oxford University Press, 2011.
8.
FrameDG: Best practice management of CINV in oncology patients: Physiology and treatment of CINV: Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol, 2010; 8(2 suppl 1):5–9.
9.
HeskethPJ, Van BelleS, AaproM, et al.: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer, 2003; 39:1074–1080.
10.
DarmaniNA, CheboluS, AmosB, AlkamT: Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav, 2011; 99:573–579.
11.
KrisMG, GrallaRJ, ClarkRA, et al.: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol, 1985; 3:1379–1384.
12.
RoilaF, BoschettiE, TonatoM, et al.: Predictive factors of delayed emesis in cisplatin- treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone: A randomized single-blind study. Am J Clin Oncol, 1991; 14:238–242.
GelingO, EichlerHG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24h after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol, 2005; 23:1289–1294.
15.
LasseterKC, GambaleJ, JinB, et al.: Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol, 2007; 47:834–840.
16.
Van LaereK, De HoonJ, BormansG, et al.: Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther, 2012; 92:243–250.
17.
NavariRM, GraySE, KerrAC: Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol, 2011; 9:188–195.
18.
RapoportBL, JordanK, BoiceJA, et al.: Aprepitant for the prevention of chemotherapy- induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double- blind study. Support Care Cancer, 2010; 18:423–431.
19.
ManskyPJ, WallerstedtDB: Complementary medicine in palliative care and cancer symptom management. Cancer J, 2006; 12:425–431.
20.
NavariRM, GraySE, KerrAC: The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 2013; 21:1655–1663.
21.
BaoT: Use of acupuncture in the control of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw, 2009; 7:606–612.
